4-Fluoro-2-(trifluoromethyl)benzaldehyde

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
195.0±40.0 °C at 760 mmHg

[ Molecular Formula ]:
C₈H₄F₄O

[ Molecular Weight ]:
192.110

[ Flash Point ]:
72.1±21.5 °C

[ Exact Mass ]:
192.019821

[ PSA ]:
17.07000

[ LogP ]:
2.32

[ Vapour Pressure ]:
0.4±0.4 mmHg at 25°C

[ Index of Refraction ]:
1.459

Click to get detail MSDS

[ Symbol ]:

GHS02, GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H226-H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
Eyeshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter

[ Hazard Codes ]:
Xi:Irritant;

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
S26-S36-S37/39

[ RIDADR ]:
UN 1989 3/PG 3

[ WGK Germany ]:
3

[ Packaging Group ]:
III

[ Hazard Class ]:
3

[ HS Code ]:
2913000090

Click to get detail synthetic route

Precursor

DownStream

[ HS Code ]: 2913000090

[ Summary ]:
HS: 2913000090 halogenated, sulphonated, nitrated or nitrosated derivatives of products of heading 2912 Educational tariff:17.0% Tax rebate rate:9.0% Regulatory conditions:none Most favored nation tariff:5.5% General tariff:30.0%

4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production.

Bioorg. Med. Chem. Lett. 19(5) , 1310-13, (2009)

The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were ev...

Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate.

J. Med. Chem. 46(24) , 5258-70, (2003)

The synthesis and preliminary evaluation of a doxorubicin-formaldehyde conjugate tethered to the nonsteroidal antiandrogen, cyanonilutamide (RU 56279), for the treatment of prostate cancer are reporte...

More Articles